Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (NERV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nerv · stock forecast · 7 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$5.00
Consensus
$5.00
+8.0% upside
Low
$5.00
Median: $5 · Last Close: $4.63
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $4.40 | ↓ 5.00% |
1-day model range: $4.35–$4.45. Peak: $4.45 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NERV · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-12 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-02-26 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-08-07 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-05-02 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-02-27 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-08-02 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-05-16 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-05-02 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Minerva Neurosciences, Inc. (NERV) stock. Of the recent 26 rating actions, 0 were upgrades and 2 were downgrades. 7 analysts currently cover NERV.
Analyst Recommendation Trends
NERV analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$20M
↑ 55.0% YoY
Revenue Next Year
$56M
↑ 185.9% YoY
EPS This Year
$-3.54
EPS Next Year
$-0.69
↓ 80.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast NERV EPS of $-3.54 for the current fiscal year, based on estimates from 1 analysts. The NERV revenue forecast is $20M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NERV stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NERV price target is $5.00 (+8.0% upside), with an analyst consensus of Buy.
The NERV short-term stock prediction for tomorrow is $4.40 (-5.00%).
Minerva Neurosciences, Inc. trades on NASDAQ under the ticker NERV. The NERV stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
NERV forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month NERV price target is $5.00, with a high forecast of $5.00 and a low of $5.00. The median price target is shown in the chart above when available. This implies +8.0% potential upside from the current price of $4.63.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.